But a study published Friday in the journal JAMA Network Open found that people with type 2 diabetes who were being treated with a class of GLP-1 drugs were significantly less likely to be diagnosed with 10 of the 13 obesity-associated cancers than those who were taking insulin
This means that if youre currently on a compounded version of Tirzepatide, youll need to switch to an FDA-approved medication before the compounding ban goes into effect on March 19, 2025
Understanding your BMI requirements for GLP-1 eligibility is the first step in determining whether you might qualify
Ready to learn more about semaglutide or get help managing your symptoms
But the short answer is not enough to keep you safe
In the aforementioned study from our group, adult mice with partial IGF-1 also displayed decreased expression of genes involved in lipid metabolism (ATP-citrate lyase, acetyl-CoA acyltransferase 1B, acetyl-CoA acetyltransferase 1) and cholesterol synthesis and transport (Both HMG-CoA reductase and synthase, LDL-related protein 1, proprotein convertase subtilisin/Kesin type 9), resulting in dyslipidaemia
